Navigation Links
Selexis SA to Present and Partner at the BIO-Europe Spring
Date:3/8/2013

Geneva, Switzerland (PRWEB) March 08, 2013

Geneva, Switzerland (PRWEB) March 8, 2013 – Selexis SA announced today the Company’s vice president of business development, Armelle Gaussin, Ph.D., will present, “Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression” as part of the Cell Therapy/Regenerative Medicine Track on Tuesday, March 12, 2013 at 3:30 PM at the BIO-Europe Spring 2013 Partnering Conference being held March 11 – 13, 2013 at the Centre Covencions Internacional Barcelona (CCIB), in Barcelona, Spain. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Selexis has developed a full expression platform based on proprietary epigenetic regulator elements, the Selexis Genetic Elements, enabling versatile and ubiquitous transgene expression in mammalian cells. This expression system has a wide range of application areas. In the cell therapy field, high and stable transgene expression is obtained in adult stem cells and also sustained upon cell differentiation both in vitro and in vivo. The platform also provides a simple, fast and reliable approach towards stable cell line development for the production of therapeutic proteins and offers a dedicated approach for difficult to express proteins.

Companies or individuals attending BIO-Europe Spring can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bes/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.

Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/BIO_Cell_therapy/regenerative_medicine/prweb10510565.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
3. Brad Paisley Partners with LiveBeyond for the "Beat This Summer Tour Presented by Cracker Barrel"
4. Celiac Disease Foundation to Present the Nation's Largest National Education Conference and Gluten-Free EXPO
5. United Representatives Invited to Sierra Leone
6. Greater representation of elderly patients in Phase III trials are needed
7. Independent panel to present findings on diagnosing gestational diabetes mellitus
8. Dr. Steve Carstensen Presents First Webinar for Dental Division of American Sleep and Breathing Academy
9. Einstein researchers present on imaging advances
10. Additional noteworthy research to be presented at the 2013 Genitourinary Cancers Symposium
11. S.T.A.R. Clinic Presents Becoming a Galactic Citizen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Maryland (PRWEB) , ... December 06, 2016 , ... ... announced the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for ... health active alerts and even taking an EKG from the watch while sharing ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/5/2016)... ... ... What: Shriners Hospitals for Children, with the help of Dimension Data, will bring ... monitor and web-enabled camera. Santa visits with children through Dimension Data’s program to connect ... is where the video connection to the North Pole will stream. Much like children ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is ... and glutathione to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is ... produce NO twice as effectively and sustains NO blood levels twice as long ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... GAINESVILLE and BOCA RATON, ... The Florida Institute for the Commercialization of Public ... it has finalized a funding agreement SegAna, LLC, ... technology developed at University of Central Florida. The ... publicly-funded research, and bridges early funding gaps for ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, ... 2021" published by MarketsandMarkets, the market is projected to reach USD ... at a CAGR of 13.5% during the forecast period of 2016 ... ...
(Date:12/5/2016)... , Dec. 5, 2016   BIOTRONIK today ... study. The study evaluates the safety and feasibility of ... an office setting. BioMonitor 2 is an ... that is placed underneath a patient,s skin to help ... (fainting). Atrial fibrillation is a leading cause of stroke ...
Breaking Medicine Technology: